--- title: "Iovance Biotherapeutics (IOVA) news: class action and offering" url: "https://aibio.space/companies/iovance-biotherapeutics/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "IOVA class action and offering news: Iovance faces securities class action and three derivative suits over 2025 revenue forecast." --- IOVA Iovance Biotherapeutics, Inc. NASDAQ · United States # Iovance Biotherapeutics (IOVA) news IOVA class action and offering news Legal · 2026-08-06 ## [Iovance faces securities class action and three derivative suits over 2025 revenue forecast](https://aibio.space/news/iovance-faces-securities-class-action-three-derivative-suits-2025/) Iovance (Nasdaq: IOVA) and unnamed officers are defendants in a California class action over 2025 revenue guidance. Derivative suits against Frederick Vogt, Jean-Marc Bellemin and others are stayed. Iovance has moved to dismiss. ## Latest Iovance Biotherapeutics news 1. 2026-08-06 Legal [Iovance defends two Delaware derivative suits over director pay and a 2024 stock offering](https://aibio.space/news/iovance-defends-two-delaware-derivative-suits-director-pay-2024-stock/) Iovance (Nasdaq: IOVA) is a nominal defendant in two Court of Chancery suits against its directors. A 2020 pay suit is consolidated and a 2024 offering suit is in motion-to-dismiss briefing. 2. 2026-06-18 Financings [Iovance Biotherapeutics files automatic shelf with $89,650,167 ATM supplement](https://aibio.space/news/iovance-biotherapeutics-files-automatic-shelf-89-650-167-atm/) The sale agreement supplement covers up to $89,650,167 of stock sold through Jefferies. Iovance's last reported sale price was $3.93 on June 17, 2026, and its 2025 net loss was $391.0 million. 3. 2025-08-22 Financings [Iovance restates Jefferies at-the-market deal, allowing sales up to $350.0 million](https://aibio.space/news/iovance-restates-jefferies-market-deal-allowing-sales-up-350-0-million/) Iovance may sell up to $350.0 million of stock through Jefferies, which can take up to 3.0% of gross proceeds. The company is not obliged to sell any shares, and its stock last traded at $2.60 on August 19, 2025. 4. 2024-11-21 Distress [Iovance moves San Carlos headquarters to smaller space, cutting monthly rent](https://aibio.space/news/iovance-moves-san-carlos-headquarters-smaller-space-cutting-monthly/) A 24-month sublease with Vaxcyte at $99,549.53 per month replaces a lease with original monthly rent of $279,540.80. ## Iovance Biotherapeutics at a glance - **Ticker**: IOVA - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $297.7 million ### Related companies - [GridAI Technologies](https://aibio.space/companies/gridai-technologies/) NASDAQ: GRDX - [Faeth Therapeutics](https://aibio.space/companies/faeth-therapeutics/) NASDAQ: FTH - [CorMedix](https://aibio.space/companies/cormedix/) NASDAQ: CRMD - [Statera Biopharma](https://aibio.space/companies/statera-biopharma/) OTC: STAB - [PureTech Health](https://aibio.space/companies/puretech-health/) LSE: PRTC - [Vera Therapeutics](https://aibio.space/companies/vera-therapeutics/) NASDAQ: VERA - [GRI Bio](https://aibio.space/companies/gri-bio/) NASDAQ: GRI - [City Therapeutics](https://aibio.space/companies/city-therapeutics/) NASDAQ: CTY ### Also on NASDAQ - [CareDx](https://aibio.space/companies/caredx/) CDNA - [CYPHERPUNK TECHNOLOGIES INC.](https://aibio.space/companies/cypherpunk-technologies/) CYPH - [GH Research](https://aibio.space/companies/gh-research/) GHRS - [Veraxa Biotech](https://aibio.space/companies/veraxa-biotech/) VRXA - [Vera Therapeutics](https://aibio.space/companies/vera-therapeutics/) VERA - [TriSalus Life Sciences](https://aibio.space/companies/trisalus-life-sciences/) TLSI ## What Iovance Biotherapeutics does Iovance Biotherapeutics develops and delivers tumor-infiltrating lymphocyte (TIL) cell therapy for solid tumor cancers. Its commercial product, Amtagvi, is for previously treated advanced melanoma, and the company's top priority is to drive its commercial success through training and collaboration with healthcare professionals at academic and community authorized treatment centers. Its development pipeline includes TIL cell therapies and next generation approaches in additional solid tumor cancers, including one-time TIL monotherapies for previously treated patients and TIL cell therapy combined with standard of care in earlier treatment settings. Two registrational trials are ongoing in frontline advanced melanoma and previously treated advanced non-small cell lung cancer. The company planned to commence a registrational trial in previously treated advanced undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma in the second quarter of 2026. In the European Union, it withdrew its initial marketing authorization application in July 2025 and is working with the European Medicines Agency to resubmit a centralized application in 2026. | Product or program | What it is | Stage | |---|---|---| | Amtagvi | TIL cell therapy for previously treated advanced melanoma | Commercial | Summarised from the company's [10-K filed Feb 24, 2026](https://www.sec.gov/Archives/edgar/data/1425205/000110465926018899/iova-20251231x10k.htm). ## Iovance Biotherapeutics annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | [$300.3 million](https://www.sec.gov/Archives/edgar/data/1425205/000110465926018899/) | [$276.2 million](https://www.sec.gov/Archives/edgar/data/1425205/000110465926018899/) | | Net income (loss) | [-$391.0 million](https://www.sec.gov/Archives/edgar/data/1425205/000110465926018899/) | [-$372.2 million](https://www.sec.gov/Archives/edgar/data/1425205/000110465926018899/) | | Cash from operations | [-$302.4 million](https://www.sec.gov/Archives/edgar/data/1425205/000110465926018899/) | [-$353.0 million](https://www.sec.gov/Archives/edgar/data/1425205/000110465926018899/) | | Cash and equivalents | [$163.1 million](https://www.sec.gov/Archives/edgar/data/1425205/000110465926091716/) | [$115.7 million](https://www.sec.gov/Archives/edgar/data/1425205/000110465926018899/) | | Short-term investments | [$133.9 million](https://www.sec.gov/Archives/edgar/data/1425205/000110465926091716/) | [$208.1 million](https://www.sec.gov/Archives/edgar/data/1425205/000110465926018899/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $110.8 million, plus short-term investments of $186.9 million, $297.7 million in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Iovance Biotherapeutics Is there a class action against Iovance Biotherapeutics? Our latest story on this, dated Aug 6, 2026: "Iovance faces securities class action and three derivative suits over 2025 revenue forecast". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/iovance-faces-securities-class-action-three-derivative-suits-2025/). Has Iovance Biotherapeutics raised money recently? Our latest story on this, dated Aug 6, 2026: "Iovance defends two Delaware derivative suits over director pay and a 2024 stock offering". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/iovance-defends-two-delaware-derivative-suits-director-pay-2024-stock/). What is the ticker symbol of Iovance Biotherapeutics? Iovance Biotherapeutics, Inc. trades under the ticker IOVA on NASDAQ. Where is Iovance Biotherapeutics listed? Iovance Biotherapeutics, Inc. is listed on NASDAQ. Our directory also records these other listings: BX:IOVA; DUS:2LB; FWB:2LB; GETTEX:2LB; HAM:2LB; HAN:2LB; LS:A2DT49; LSE:0JDK; LSX:A2DT49; MUN:2LB; SWB:2LB; TRADEGATE:2LB; XETR:2LB. What is the SEC CIK of Iovance Biotherapeutics? The SEC Central Index Key (CIK) for Iovance Biotherapeutics, Inc. is 1425205. Its filings are on SEC EDGAR. How many shares does Iovance Biotherapeutics have outstanding? 452,971,432 shares as of 2026-07-29, per the cover page of its 10-Q filed 2026-08-06. Which country or territory is Iovance Biotherapeutics listed under? Our directory records Iovance Biotherapeutics, Inc. under United States. What does Iovance Biotherapeutics do? Our directory classifies Iovance Biotherapeutics, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline. What is the ISIN of Iovance Biotherapeutics? The ISIN recorded for Iovance Biotherapeutics, Inc. is US4622601007. Does aibio.space cover Iovance Biotherapeutics? aibio.space lists Iovance Biotherapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Iovance Biotherapeutics incorporated? SEC records list its state or country of incorporation as DE. What does Iovance Biotherapeutics develop? Iovance Biotherapeutics develops and delivers tumor-infiltrating lymphocyte (TIL) cell therapy for solid tumor cancers. Its commercial product, Amtagvi, is for previously treated advanced melanoma, and the company's top priority is to drive its commercial success through training and collaboration with healthcare professionals at academic and community authorized treatment centers. What is Amtagvi from Iovance Biotherapeutics? Amtagvi: TIL cell therapy for previously treated advanced melanoma Stage: Commercial. Is Iovance Biotherapeutics profitable? Iovance Biotherapeutics, Inc. reported a net loss of $391.0 million for the fiscal year ended Dec 31, 2025, and used $302.4 million of cash in operations, per its annual report to the SEC. How much does Iovance Biotherapeutics spend on research and development? $300.3 million in the fiscal year ended Dec 31, 2025, per its annual report. ## Investor discussion: Iovance Biotherapeutics Members talk about Iovance Biotherapeutics (IOVA). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Iovance Biotherapeutics, newest first. Each line links the filing it comes from. 1. 2026-06-18 Financings Set up an at-the-market program to sell shares over time. SEC Form S-3ASR. [Source](https://www.sec.gov/Archives/edgar/data/1425205/000110465926075778/iova-20260618xs3asr.htm) 2. 2026-06-10 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1425205/000110465926072408/tm2613648d1_ex99-1.htm) 3. 2026-05-07 Legal Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1425205/000110465926056778/iova-20260331x10q.htm) 4. 2025-08-22 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1425205/000110465925081949/tm2524059-1_424b5.htm) 5. 2025-08-07 Legal Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1425205/000155837025010807/iova-20250630x10q.htm) 6. 2024-11-21 Distress Reported the end of a material agreement. SEC Form 8-K (Items 1.01,1.02). [Source](https://www.sec.gov/Archives/edgar/data/1425205/000110465924121612/tm2429156d1_8k.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:IOVA on TradingView](https://www.tradingview.com/symbols/NASDAQ-IOVA/). ## SEC filings and registration - **SEC name**: Iovance Biotherapeutics, Inc. - **CIK**: 1425205 - **Industry (SIC)**: Biological Products, (No Diagnostic Substances) (2836) - **US tickers**: IOVA (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**: Accelerated filer - **Business address**: 825 INDUSTRIAL ROAD, SAN CARLOS, CA, 94070 - **Phone**: 6502607120 - **Shares outstanding**: 452,971,432 as of 2026-07-29 (10-Q filed 2026-08-06) - **Former names**: Lion Biotechnologies, Inc.; Genesis Biopharma, Inc; FREIGHT MANAGEMENT CORP ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1425205/000110465926113763/tm2627047d1_8k.htm) filed 2026-10-05 - [8-K](https://www.sec.gov/Archives/edgar/data/1425205/000110465926111583/tm2626507d1_8k.htm) filed 2026-09-29 - [8-K](https://www.sec.gov/Archives/edgar/data/1425205/000110465926092145/tm2622463d1_8k.htm) filed 2026-08-06 - [10-Q](https://www.sec.gov/Archives/edgar/data/1425205/000110465926091716/iova-20260630x10q.htm) filed 2026-08-06 - [8-K](https://www.sec.gov/Archives/edgar/data/1425205/000110465926091619/tm2622322d1_8k.htm) filed 2026-08-06 - [8-K](https://www.sec.gov/Archives/edgar/data/1425205/000110465926080409/tm2618989d1_8k.htm) filed 2026-07-02 - [8-K](https://www.sec.gov/Archives/edgar/data/1425205/000110465926072408/tm2613648d1_8k.htm) filed 2026-06-10 - [8-K](https://www.sec.gov/Archives/edgar/data/1425205/000110465926056782/tm2613648d1_8k.htm) filed 2026-05-07 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001425205), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Iovance Biotherapeutics, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker IOVA, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Iovance Biotherapeutics, Inc. - **Ticker**: IOVA - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Biotechnology - **ISIN**: US4622601007 - **Other listed symbols**: BX:IOVA; DUS:2LB; FWB:2LB; GETTEX:2LB; HAM:2LB; HAN:2LB; LS:A2DT49; LSE:0JDK; LSX:A2DT49; MUN:2LB; SWB:2LB; TRADEGATE:2LB; XETR:2LB - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-IOVA/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/iovance-biotherapeutics/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Iovance Biotherapeutics (IOVA) news: class action and offering", 2026-10-31, https://aibio.space/companies/iovance-biotherapeutics/